Home
Storia in 1 fonti
Clinical Success Is No Longer One Number
By Andreas Dimakakos Director of Clinical Data, Kate Smietana Director, Knowledge and Thought Leadership, Panos Karelis VP of Commercial, Dimitris Skaltsas Co-founder & CEO | In biopharmaceutical R&D, where fewer than 1 in 10 development programs ultimately reach approval, risk assessment remains central to portfolio strategy and investment decisions.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
A $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. | This…
- ·
Clinical Success Is No Longer One Number
By Andreas Dimakakos Director of Clinical Data, Kate Smietana Director, Knowledge and Thought Leadership, Panos Karelis VP of Commercial, Dimitris Skaltsas Co-founder & CEO | In…
- ·
9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experience
The pharmaceutical industry is reaching a turning point in patient support. | Life sciences leaders say patient support is falling short. New research reveals why 9 of the top 10…
- ·
FDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutiny
In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has
- ·
The Unified Ecosystem: How To Integrate Intelligence and Execution for Better Patient Outcomes
For manufacturers evaluating the future of their partnership strategy, this whitepaper offers a perspective on how connected operating models help organizations anticipate…